Aridis Pharmaceuticals Inc (ARDS)

$0.00 0.00 (N/A)
Market Cap 5,000.00
Revenue (ttm) 3.09M
Net Income (ttm) -30.37M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -982.85%
Debt to Equity Ratio 0.00
Volume 10,700
Avg Vol 8,610
Day's Range N/A - N/A
Shares Out 53.32M
Stochastic %K 50%
Beta 12.09
Analysts Strong Buy
Price Target $2.00

Company Profile

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquir...

Industry: Biotechnology
Sector: Healthcare
Phone: 408 385 1742
Fax: 408 356 9548
Address:
983 University Avenue, Building B, Los Gatos, United States
ChiefStockTraderJr
ChiefStockTraderJr Jun. 27 at 1:36 PM
$ARDS Would you classify this stock as a ZOMBIE company? Looks like it to me.
0 · Reply
xersdave
xersdave Jun. 19 at 1:25 PM
$ARDS Selling for a tax loss sometime in October. Thx for nothing Vu. Rather than sell the whole company your stubbornness allowed you to go under. We, the shareholders thank you so very much. Adios and good riddance.
1 · Reply
xersdave
xersdave Jun. 16 at 3:40 PM
$ARDS
0 · Reply
ReturnOfEsquire
ReturnOfEsquire Jun. 13 at 3:15 AM
$ARDS Lesson here is words are worthless. You can't believe a word these fuckers (directors) say, and definitely ignore any douchbag who claims to have inside information.
1 · Reply
ChiefStockTraderJr
ChiefStockTraderJr May. 20 at 3:30 PM
$ARDS When it comes down to it, I lost everything I invested in this stock. I suppose if false hope was not spoon fed to me, I would have sold earlier. Limited my losses. I am not an insider. I think Vu really screwed us. Should have known not to trust the guy with his lack of transparency. He left us all in the dark and closed shop. Turned off the lights and left us sitting in the dark talking amongst ourselves. I know nothing about backroom deals going on. I like to believe that there is some sliver of hope as remote as that sounds for this company. Not false or fake made up hope stories but real hope. How do you feel? You paid a lot to get here.
2 · Reply
ReturnOfEsquire
ReturnOfEsquire May. 13 at 9:00 PM
$ARDS Buyout yet? No? I'll check back next month.
4 · Reply
Phaaisatroll
Phaaisatroll May. 8 at 10:16 AM
$ARDS for the people who still didn't see the news. Aridis is still alive and trying to finalize the 2 deals. If that's successful then things could be good and if its not successful then not good. https://www.aridispharma.com/wp-content/uploads/2025/04/Aridis-PR-Corporate-Update-Web-Apr2025_-003.pdf
1 · Reply
awfullyeducated
awfullyeducated May. 5 at 9:27 PM
$ARDS Yes I'll have a write-off in ARDS myself! Their approach to move away from traditional antibiotics into a new technology made sense to me. And they got organizations to pay for some of their earlier work, they were better then at getting funding EXAMPLE: Efficiently obtained funding for trials - example - by the Cystic Fibrosis Foundation for $7.5 million.
0 · Reply
Shanenobody
Shanenobody May. 5 at 8:06 PM
$ARDS 19,000 shares traded today. Hmmm.
1 · Reply
BostonDave
BostonDave May. 5 at 1:00 PM
$ARDS They will screw the shareholders, hand the company over to Streeterville to survive, and we'll all have a tax deduction.
1 · Reply
Latest News on ARDS
No data available.
ChiefStockTraderJr
ChiefStockTraderJr Jun. 27 at 1:36 PM
$ARDS Would you classify this stock as a ZOMBIE company? Looks like it to me.
0 · Reply
xersdave
xersdave Jun. 19 at 1:25 PM
$ARDS Selling for a tax loss sometime in October. Thx for nothing Vu. Rather than sell the whole company your stubbornness allowed you to go under. We, the shareholders thank you so very much. Adios and good riddance.
1 · Reply
xersdave
xersdave Jun. 16 at 3:40 PM
$ARDS
0 · Reply
ReturnOfEsquire
ReturnOfEsquire Jun. 13 at 3:15 AM
$ARDS Lesson here is words are worthless. You can't believe a word these fuckers (directors) say, and definitely ignore any douchbag who claims to have inside information.
1 · Reply
ChiefStockTraderJr
ChiefStockTraderJr May. 20 at 3:30 PM
$ARDS When it comes down to it, I lost everything I invested in this stock. I suppose if false hope was not spoon fed to me, I would have sold earlier. Limited my losses. I am not an insider. I think Vu really screwed us. Should have known not to trust the guy with his lack of transparency. He left us all in the dark and closed shop. Turned off the lights and left us sitting in the dark talking amongst ourselves. I know nothing about backroom deals going on. I like to believe that there is some sliver of hope as remote as that sounds for this company. Not false or fake made up hope stories but real hope. How do you feel? You paid a lot to get here.
2 · Reply
ReturnOfEsquire
ReturnOfEsquire May. 13 at 9:00 PM
$ARDS Buyout yet? No? I'll check back next month.
4 · Reply
Phaaisatroll
Phaaisatroll May. 8 at 10:16 AM
$ARDS for the people who still didn't see the news. Aridis is still alive and trying to finalize the 2 deals. If that's successful then things could be good and if its not successful then not good. https://www.aridispharma.com/wp-content/uploads/2025/04/Aridis-PR-Corporate-Update-Web-Apr2025_-003.pdf
1 · Reply
awfullyeducated
awfullyeducated May. 5 at 9:27 PM
$ARDS Yes I'll have a write-off in ARDS myself! Their approach to move away from traditional antibiotics into a new technology made sense to me. And they got organizations to pay for some of their earlier work, they were better then at getting funding EXAMPLE: Efficiently obtained funding for trials - example - by the Cystic Fibrosis Foundation for $7.5 million.
0 · Reply
Shanenobody
Shanenobody May. 5 at 8:06 PM
$ARDS 19,000 shares traded today. Hmmm.
1 · Reply
BostonDave
BostonDave May. 5 at 1:00 PM
$ARDS They will screw the shareholders, hand the company over to Streeterville to survive, and we'll all have a tax deduction.
1 · Reply
BostonDave
BostonDave May. 5 at 12:49 PM
$ARDS Looks like it's over.
1 · Reply
BostonDave
BostonDave May. 5 at 12:49 PM
$ARDS The Company has been working with its lead lender Streeterville Capital, LLC to service the April 26th, 2023 loan that has been due for full repayment since April 26th, 2024. The Company recently received a failure to pay notice from Streeterville Capital that becomes an Event of Default by April 30th, 2025. The Company’s near-term goals will be to successfully complete the business objectives described above in order to service the Streeterville loan and other debts that have accrued since the start of the COVID-19 pandemic, and to become current on its SEC filings as soon as the revenues from the AR-501 Asset Acquisition Terms Agreement and/or the AR-301 investment are received.
0 · Reply
BostonDave
BostonDave May. 5 at 12:47 PM
$ARDS New corporate update April 30th. https://www.aridispharma.com/wp-content/uploads/2025/04/Aridis-PR-Corporate-Update-Web-Apr2025_-003.pdf
2 · Reply
xersdave
xersdave Apr. 30 at 9:36 AM
$ARDS
0 · Reply
xersdave
xersdave Apr. 30 at 9:35 AM
$ARDS
0 · Reply
ReturnOfEsquire
ReturnOfEsquire Apr. 25 at 2:52 AM
$ARDS
0 · Reply
Phaaisatroll
Phaaisatroll Apr. 23 at 7:41 PM
$ARDS post from an AstraZeneca employee.
1 · Reply
Bigos
Bigos Apr. 21 at 7:26 PM
$ARDS The Pope died of a stroke (he was old). And the moron @Phaaisatroll claims that ARDS could have prevented his cause of death. ARDS does not have a drug candidate for strokes.
1 · Reply
Phaaisatroll
Phaaisatroll Apr. 21 at 10:26 AM
$ARDS the pope dies and our drug could have saved his life. These lung infections are so deadly especially for old people. There has to be somebody interested to develop this drug.
0 · Reply
ReturnOfEsquire
ReturnOfEsquire Apr. 19 at 12:47 AM
$ARDS Buyout yet? No? I'll check back next month. Whenever management engages retail shareholders, bad times are ahead...always.
0 · Reply
kotatsu
kotatsu Apr. 16 at 11:34 PM
$ARDS Unfortunately, we lost. In my opinion, it is unlikely that Vu will be able to close the deal. This company was sunk to the bottom of the OTC by Vu's mismanagement at key points. And our mistake was investing in a company with no real technology, no future, no competence, no sincerity. I have no choice but to wait.
0 · Reply
Bigos
Bigos Apr. 13 at 5:40 PM
$ARDS Bret, thanks for the update. That sucks! Sounds like possible fraud.
0 · Reply